HONG KONG/BEIJING (Reuters) - Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China’s National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.
The experimental COVID-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech’s partner Pfizer Inc said on Monday.
Shanghai Fosun said in a company filing that its unit will begin a Phase II clinical trial in China for the candidate when the conditions are ready.
Reporting by Twinnie Siu and Roxanne Liu. Editing by Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.